Literature DB >> 1467535

Systemic lupus erythematosus.

A J Swaak1, J C Nossent, R J Smeenk.   

Abstract

The reported change in the incidence of systemic lupus erythematosus (SLE) is mainly due to a greater awareness of the disease, and to the introduction of serological detection methods such as the LE cell assay and subsequently a variety of other antinuclear antibody assays. SLE is seldom preceded by rheumatoid arthritis, nor does SLE often develop in patients with rheumatoid arthritis. In a substantial proportion of our SLE patients, discoid LE occurred first. On analyzing the literature no evidence could be found that nowadays less severe SLE is diagnosed. Also, in the last three decades no change has been observed in the prevalence of clinical features in large groups of patients with SLE. These data indicate that there has been no change in the expression or prognosis of SLE in recent decades.

Entities:  

Mesh:

Year:  1992        PMID: 1467535     DOI: 10.1007/bf02591422

Source DB:  PubMed          Journal:  Int J Clin Lab Res        ISSN: 0940-5437


  5 in total

1.  Connective Tissue Disease-associated Interstitial Lung Disease: A review.

Authors:  Markus Gutsche; Glenn D Rosen; Jeffrey J Swigris
Journal:  Curr Respir Care Rep       Date:  2012-09-21

2.  Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus.

Authors:  Ewa Robak; Agnieszka Wierzbowska; Magdalena Chmiela; Liliana Kulczycka; Anna Sysa-Jedrejowska; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

3.  Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus.

Authors:  E Robak; J Z Błoński; J Bartkowiak; H Niewiadomska; A Sysa-Jedrzejowska; T Robak
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

4.  Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus.

Authors:  E Robak; P Smolewski; A Woźniacka; A Sysa-Jedrzejowska; T Robak
Journal:  Mediators Inflamm       Date:  2004-06       Impact factor: 4.711

5.  Tumour necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6) and their soluble receptors (sTNF-alpha-Rp55 and slL-6R) serum levels in systemic lupus erythematodes.

Authors:  E Robak; A Sysa-Jedrzejowska; T Robak; H Stepień; A Woźniacka; E Waszczykowsk
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.